Naked Shorts at the Supreme Court Dec 1, 2015 2:00 PM

New Post Public Reply Private Reply Replies (2) Message Board
AlanC doubleJ23 #16146
Naked Shorts at the Supreme Court

Dec 1, 2015 2:00 PM EST

By Noah Feldman

When you’re trading securities, you generally think about being regulated by the Securities and Exchange Commission and federal law. Should you be worried about state law, too? That question isn't merely theoretical, as shown by the naked short selling case that was argued Tuesday before the U.S. Supreme Court. The answer has practical consequences for traders of all kinds.

The case, Merrill Lynch v. Manning, arises from allegations by individual shareholders in Escala Group Inc., that traders at Merrill Lynch, Knight Equity Markets and UBS Securities, among others, engaged in naked short selling to manipulate the value of the stock. In essence, the original plaintiffs alleged that the traders made short sales without bothering to borrow the securities that would be needed to cover the trade.

That's illegal -- sort of. No federal or state law directly criminalizes naked short selling. However, an SEC rule called Regulation SHO says a broker-dealer must have “reasonable grounds” to believe that it could borrow and deliver the security within three days. If the broker-dealer fails to deliver for 13 days, the regulation imposes a “close out” duty to purchase and deliver securities “of like kind and quantity.”

Given that federal law doesn't obviously impose a clear form of liability for naked short selling, the plaintiffs in the case went to New Jersey state court instead. They alleged violations of the state's RICO law, the one designed to outlaw conspiracies of the kind traditionally used by organized crime. RICO laws require specification of particular legal violations; the plaintiffs said the defendants had committed acts of securities fraud and theft under New Jersey law. For good measure, they also said the defendants were liable under New Jersey’s unwritten common law for breach of contract, negligence and other assorted claims.

To explain to the state court what the broker-dealers had done wrong, the plaintiffs described federal Regulation SHO, which they said the defendants had violated. But they were careful to say that their state law case didn't depend on there being a violation of the federal regulation.

Lawyers for Merrill Lynch and the other defendants did what any lawyer would’ve done under the circumstances: They sought to move the case to federal court, where they’d be able to argue that federal law controls naked short selling and that they hadn’t broken it. A federal district court said the case belonged in federal court. But the U.S. Court of Appeals for the 3rd Circuit disagreed, and the case ended up before the Supreme Court.

Who's right? The best argument for allowing the case to go forward in state court is that state securities regulations have been around since long before there was an SEC. The Securities Exchange Act of 1933 was famously drafted over the weekend of April 8, 1933, in a hotel room by the dream team of Thomas Corcoran, Benjamin Cohen and James Landis, three brilliant students of Felix Frankfurter who followed his marching orders in drafting legislation for Franklin Roosevelt’s administration.

By then, every state but Nevada had enacted some version of a general law prohibiting deceptive securities practices. These state laws are called “blue sky laws,” because, as the Supreme Court put it in 1917, they outlaw “speculative schemes which have no more basis than so many feet of ‘blue sky.’”

Congress never said that it was displacing the states’ blue sky laws, which strongly implies that it should still be possible to go to state court in a securities case where federal law doesn’t cover the precise situation.

The strongest counterargument is that it’s highly inefficient to subject securities regulation to the laws of 50 states plus federal law. A national industry requires national standards. Compliance costs are high enough without requiring broker-dealers to worry about divergent regulations in different places.

What makes it tricky to predict the outcome in this case is that the usual liberal and conservative positions produce contradiction.

Generally, the liberals on today’s court like centralized national regulation and favor federal law. So you’d expect them to want to say that this is a federal issue that belongs in federal court.

But that would be a pro-defendant ruling in this case, because Merrill Lynch and the other defendants would probably get a more sympathetic hearing from a federal court, which could find they aren’t liable under federal law. That’s awkward for the liberals, because it makes them look soft on stock manipulators. It also makes them look as if they’re siding with the banks against the little guy, which the liberals hate to do.

For the conservatives, the problem is that respecting state law, the federalist position, puts them in a position of helping pesky plaintiffs’ lawyers who, conservatives believe, are trying to harass defendants for money. The court’s conservatives dislike and distrust plaintiffs’ side securities lawyers, and won’t want to give them the tool of going to state court. They think such litigation adds costs and inefficiency without improving securities markets.

Given the dual tension, my instinct is that the conservatives will win and the lawsuit will be allowed to go forward. But this one will be close -- so call your compliance officer today. He or she may be your best friend.

This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.

To contact the author of this story:
Noah Feldman at nfeldman7@bloomberg.net


http://www.bloombergview.com/articles/2015-12...reme-court
Go CTIX!!!

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 26

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

NuCana Discontinues Phase 2 Colorectal Cancer Study

Updated Category News Views 146

NuCana Provides Update on Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study Discontinued Following Initial Analysis Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab NuCana plc (NASDAQ: NCNA) has shared important updates about its clinical trials focused on innovative treatments for colorectal cancer. The company has made the decision to discontinue...

Continue Reading
Brøndbyernes IF Football Meeting - Key Highlights Recap

Updated Category News Views 179

Overview of the Annual General Meeting for Brøndbyernes IF Football A/S BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10 This report summarizes the outcomes of the annual general meeting conducted by Brøndbyernes IF Football A/S. Key Date and Location The annual shareholders meeting took place, gathering stakeholders and shareholders at the club's headquarters. A...

Continue Reading
Uncovering the Wealth from Investing in BlackRock

Updated Category News Views 314

The Potential Growth of $1000 in BlackRock Investors often wonder how their money would grow over time if invested in strong companies. Recently, we looked into BlackRock, Inc., known by its stock ticker BLK. Over a span of 15 years, investing just $1000 into BlackRock stocks would yield an impressive value today. According to current evaluations, if you had made that...

Continue Reading
Zealand Pharma Advances Glepaglutide Approval for SBS Treatment

Updated Category News Views 267

Glepaglutide Submission to EMA Marks Significant Progress Zealand Pharma A/S, a pioneering biotechnology company, has recently shared exciting news about its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its innovative drug, glepaglutide. This long-acting GLP-2 analog is specifically designed for treating adults suffering from short...

Continue Reading
Seven Gables Real Estate Partners with Local Logic for Insights

Updated Category News Views 40

Seven Gables Real Estate Partners with Local Logic In a significant move that underscores their dedication to innovation, Seven Gables Real Estate has announced an exciting partnership with Local Logic, a leader in location intelligence. This collaboration is set to incorporate Local Logic's cutting-edge products—Local Content, Local Search, and NeighborhoodWrap—into...

Continue Reading